NovalGen is a privately held immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer. Their dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated bispecific antibody products that are tailored to the needs of the patient, enabling life-enhancing treatments for people with hematologic and solid tumors. The company’s lead program, NVG-111, is an ROR1 targeting bispecific antibody T-Cell engager using our breakthrough bispecific technology which is expected to enter clinical development in H1 2021.